StockData

Evolus vs Organogenesis

EOLS and ORGO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How EOLS and ORGO compare

Evolus is the larger company, worth 4.2 times as much as Organogenesis ($442M against $104M).

Evolus grew revenue faster over the last twelve months (13.9% versus 6.5% for Organogenesis).

Evolus keeps more of each dollar of sales as profit, with a net margin of −10.8% compared with −18.4% at Organogenesis.

Organogenesis scores higher on the StockData Score (10 against 6 for Evolus), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricEOLSORGO
Size and price
Market cap$442M$104M
Share price$6.69$0.812
Change, 1 year−7.3%−86.7%
Change, 5 years17.4%−91.8%
Beta (5Y)1.930.57
Employees334854
StockData Score
Total score610 (better)
Valuation score11
Growth score2 (better)1
Performance score23 (better)
Health score15 (better)
Dividend score00
Valuation
P/S1.4×0.2× (better)
P/B–0.7×
P/FCF–5.0×
FCF yield−4.1%20.0% (better)
Growth
Revenue growth (TTM)13.9% (better)6.5%
Revenue growth, 5Y average39.4% (better)10.8%
EPS growth, 5Y average–0.00%
Profitability
Gross margin66.7%–
Operating margin−5.9% (better)−7.8%
Net margin−10.8% (better)−18.4%
FCF margin−5.8%4.6% (better)
Return on equity–−44.1%
Return on invested capital−20.2% (better)−21.7%
Financial health
Debt / equity–0.00
Interest coverage−1.2×–
Current ratio1.703.52 (better)
Altman Z-score−1.531.26 (better)
Piotroski F-score25 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions84.0%53.2%
Held by insiders4.1%–
Insider net buying, 12 months−$1.8M−$988K (better)
Short interest, % of float9.5%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.